Pharmaceutical News

RSS

GLP-1 discontinuation associated with more weight gain and pregnancy complications

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain more weight and have higher risks of diabetes and hypertensive disorders during pregnancy, and experienced preterm delivery more so than people who had never taken GLP-1 drugs.

24 Nov 2025

Study finds GLP-1 drugs improve strength and reverse aging biology in mice

Researchers showed that GLP-1 receptor agonism counteracts aging across multiple organs in mice, improving strength and reversing molecular aging signatures without meaningful effects on body weight. These benefits depended largely on hypothalamic GLP-1R signaling and closely mirrored the anti-aging patterns produced by rapamycin.

23 Nov 2025

Take-home methadone provides a lifesaving bridge to recovery after hospitalization

For patients recovering from opioid use disorder, particularly from drugs like fentanyl or heroin, the days immediately following a hospital stay are among the most dangerous.

22 Nov 2025

AMI urges stronger and more equitable global action plan on antimicrobial resistance

In World Antimicrobial Resistance Awareness Week (WAAW), Applied Microbiology International (AMI) has urged global policymakers to strengthen the revised Global Action Plan on Antimicrobial Resistance (GAP-AMR), calling for a more inclusive, clear and equitable approach to tackling one of the world's most urgent health challenges.

20 Nov 2025

Searches for “Ozempic face” surge as people look for filler-based solutions

Public interest in “Ozempic face” rose sharply from 2022 to 2025, mirrored by increased searches for nonsurgical facial filler procedures. Surgical terms showed neutral or negative associations, indicating consumers are primarily exploring filler-based solutions for GLP-1RA-related facial volume loss.

20 Nov 2025

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.

20 Nov 2025

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects.

20 Nov 2025

Oral semaglutide delivers real-world drops in blood sugar and weight in diabetes trial

Oral semaglutide delivered meaningful reductions in HbA1c and body weight among GLP-1RA-naïve adults with type 2 diabetes in a Dutch real-world cohort. Lipid levels and blood pressure showed only small changes, reflecting modest cardiometabolic effects outside glucose and weight control.

18 Nov 2025

Tirzepatide reveals a brain signal that predicts returning food preoccupation

Researchers implanted electrodes in the human nucleus accumbens to track brain activity during severe food preoccupation in an individual taking tirzepatide. They found that a delta–theta biomarker disappeared during symptom-free periods and re-emerged weeks before relapse, suggesting a possible neural marker of vulnerability to dysregulated eating.

18 Nov 2025

Alzheimer’s drugs improve key cognitive skills in children with autism and low IQ

The review synthesizes evidence on whether Alzheimer’s disease medications can improve neurocognitive outcomes in children and adolescents with autism and low IQ. Across 12 studies, preliminary findings show promising gains in language, executive function, learning and memory, and general cognitive ability, particularly in younger children.

18 Nov 2025

Year-long adherence to buprenorphine sharply reduces overdose risk in young people

New research from Mass General Brigham finds that adolescents and young adults who stayed on the medication buprenorphine for at least a year had markedly lower risks of opioid overdose and hospitalization compared with peers who discontinued medication early or took it inconsistently.

18 Nov 2025

Yale study exposes unequal access to new medicines after clinical trials

A new study led by Yale's Jennifer Miller, PhD, found that medicines are not physically accessible in many of the countries where they are tested for FDA approval.

17 Nov 2025

Brain recordings reveal short-lived effects of tirzepatide on food cravings

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" thought to be involved in food noise – but only temporarily.

17 Nov 2025

New malaria treatment holds promise against rising drug resistance

The first new malaria treatment in decades holds promise against rising drug resistance after Swiss drugmaker Novartis announced it was as effective at treating the disease as established treatments.

17 Nov 2025

Fondazione Telethon achieves milestone with Waskyra approval for Wiskott-Aldrich Syndrome

Fondazione Telethon announces the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorization in the European Union for Waskyra, an ex vivo gene therapy for Wiskott-Aldrich Syndrome (WAS), a rare and life-threatening primary immunodeficiency.

14 Nov 2025

Portrayal of lorazepam use inTV series associated with increased online searches for the drug

In season three of the hit television series The White Lotus, the character Victoria Ratliff takes the prescription anti-anxiety medication lorazepam to help with her social anxiety and inability to sleep.

14 Nov 2025

Off-label GLP-1 use highlights the cultural pressures driving body anxieties

New obesity drugs that were designed to treat diabetes and obesity are increasingly being used off-label by people without these conditions to achieve slimness and social approval rather than health gains. This perspective maps how such pharmacological thinness interacts with stigma, beauty ideals, digital culture, and inequality, and calls for multinational, intersectional research to understand its full impact.

13 Nov 2025

Common gout drug shows promise in preventing heart attacks and strokes

A widely-used, inexpensive gout drug could reduce heart attacks and strokes in people with cardiovascular disease, according to a new Cochrane review.

12 Nov 2025

Extended use of anti-clotting drugs reduces risk of recurrent blood clots

Extending anti-clotting drugs beyond the initial treatment period of at least 90 days after a first blood clot is linked to lower rates of new clots developing compared with stopping treatment, finds a US study published by The BMJ today.

12 Nov 2025

No, taking paracetamol while pregnant doesn’t cause autism or ADHD, major review finds

Researchers reviewed nine systematic reviews on paracetamol use during pregnancy and found that while some studies suggested links to ADHD or autism, the evidence was of low quality and confounded by shared familial factors. Sibling-controlled analyses showed no causal relationship between prenatal paracetamol exposure and neurodevelopmental disorders in children.

11 Nov 2025

1
2
3
4
...
1458
Next

Pharmaceutical News

GLP-1 discontinuation associated with more weight gain and pregnancy complications

Study finds GLP-1 drugs improve strength and reverse aging biology in mice

Take-home methadone provides a lifesaving bridge to recovery after hospitalization

AMI urges stronger and more equitable global action plan on antimicrobial resistance

Searches for “Ozempic face” surge as people look for filler-based solutions

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Oral semaglutide delivers real-world drops in blood sugar and weight in diabetes trial

Tirzepatide reveals a brain signal that predicts returning food preoccupation

Alzheimer’s drugs improve key cognitive skills in children with autism and low IQ

Year-long adherence to buprenorphine sharply reduces overdose risk in young people

Yale study exposes unequal access to new medicines after clinical trials

Brain recordings reveal short-lived effects of tirzepatide on food cravings

New malaria treatment holds promise against rising drug resistance

Fondazione Telethon achieves milestone with Waskyra approval for Wiskott-Aldrich Syndrome

Portrayal of lorazepam use inTV series associated with increased online searches for the drug

Off-label GLP-1 use highlights the cultural pressures driving body anxieties

Common gout drug shows promise in preventing heart attacks and strokes

Extended use of anti-clotting drugs reduces risk of recurrent blood clots

No, taking paracetamol while pregnant doesn’t cause autism or ADHD, major review finds

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News